Home >> Infectious Diseases >> Infectious Diseases >> Baked Goods >> Technology & Media >>

Resistant Pseudomonas Aeruginosa Infections - Pipeline Review, H1 2015

Published: Apr-2015 | Format: PDF | Global Markets Direct | Number of pages: 67 | Code: MRS - 18269

Resistant Pseudomonas Aeruginosa Infections - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Resistant Pseudomonas Aeruginosa Infections - Pipeline Review, H1 2015’, provides an overview of the Resistant Pseudomonas Aeruginosa Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Resistant Pseudomonas Aeruginosa Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Resistant Pseudomonas Aeruginosa Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Resistant Pseudomonas Aeruginosa Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Resistant Pseudomonas Aeruginosa Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Resistant Pseudomonas Aeruginosa Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Resistant Pseudomonas Aeruginosa Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Resistant Pseudomonas Aeruginosa Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Resistant Pseudomonas Aeruginosa Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Resistant Pseudomonas Aeruginosa Infections Overview 8
Therapeutics Development 9
Pipeline Products for Resistant Pseudomonas Aeruginosa Infections - Overview 9
Pipeline Products for Resistant Pseudomonas Aeruginosa Infections - Comparative Analysis 10
Resistant Pseudomonas Aeruginosa Infections - Therapeutics under Development by Companies 11
Resistant Pseudomonas Aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes 12
Resistant Pseudomonas Aeruginosa Infections - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Resistant Pseudomonas Aeruginosa Infections - Products under Development by Companies 15
Resistant Pseudomonas Aeruginosa Infections - Products under Investigation by Universities/Institutes 16
Resistant Pseudomonas Aeruginosa Infections - Companies Involved in Therapeutics Development 17
Achaogen Inc. 17
AstraZeneca PLC 18
Biolytics Pharma 19
CSA Biotechnologies LLC 20
LegoChem Biosciences, Inc 21
Melinta Therapeutics, Inc 22
Microbion Corporation 23
Phico Therapeutics Ltd. 24
Phylogica Limited 25
Shionogi & Co., Ltd. 26
Zambon Company S.p.A. 27
Resistant Pseudomonas Aeruginosa Infections - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
ACHN-975 Prodrug - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Biologic for Pseudomonas Aeruginosa Infection - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Cephalosporin + Beta-Lactamase Inhibitor - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
CSA-13 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
G-10 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
LCB-100200 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Monoclonal Antibodies for Gram-Negative Bacterial Infections - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
PT-3.33 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
RXP-763 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
RXP-766 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
RXP-770 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
RXP-792 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
RXP-793 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
RXP-808 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
RXP-873 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
S-649266 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Small Molecule for Chronic Wound Infection and Bacterial Infections - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecules for Gram-Negative Bacterial Infections - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Small Molecules for Multi-Drug Resistant Bacterial Infections - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ZP-046 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Resistant Pseudomonas Aeruginosa Infections - Recent Pipeline Updates 62
Resistant Pseudomonas Aeruginosa Infections - Dormant Projects 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67

List of Tables
Number of Products under Development for Resistant Pseudomonas Aeruginosa Infections, H1 2015 9
Number of Products under Development for Resistant Pseudomonas Aeruginosa Infections - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Resistant Pseudomonas Aeruginosa Infections - Pipeline by Achaogen Inc., H1 2015 17
Resistant Pseudomonas Aeruginosa Infections - Pipeline by AstraZeneca PLC, H1 2015 18
Resistant Pseudomonas Aeruginosa Infections - Pipeline by Biolytics Pharma, H1 2015 19
Resistant Pseudomonas Aeruginosa Infections - Pipeline by CSA Biotechnologies LLC , H1 2015 20
Resistant Pseudomonas Aeruginosa Infections - Pipeline by LegoChem Biosciences, Inc, H1 2015 21
Resistant Pseudomonas Aeruginosa Infections - Pipeline by Melinta Therapeutics, Inc, H1 2015 22
Resistant Pseudomonas Aeruginosa Infections - Pipeline by Microbion Corporation, H1 2015 23
Resistant Pseudomonas Aeruginosa Infections - Pipeline by Phico Therapeutics Ltd., H1 2015 24
Resistant Pseudomonas Aeruginosa Infections - Pipeline by Phylogica Limited, H1 2015 25
Resistant Pseudomonas Aeruginosa Infections - Pipeline by Shionogi & Co., Ltd., H1 2015 26
Resistant Pseudomonas Aeruginosa Infections - Pipeline by Zambon Company S.p.A., H1 2015 27
Assessment by Monotherapy Products, H1 2015 28
Assessment by Combination Products, H1 2015 29
Number of Products by Stage and Target, H1 2015 31
Number of Products by Stage and Mechanism of Action, H1 2015 33
Number of Products by Stage and Route of Administration, H1 2015 35
Number of Products by Stage and Molecule Type, H1 2015 37
Resistant Pseudomonas Aeruginosa Infections Therapeutics - Recent Pipeline Updates, H1 2015 62
Resistant Pseudomonas Aeruginosa Infections - Dormant Projects, H1 2015 65

List of Figures
Number of Products under Development for Resistant Pseudomonas Aeruginosa Infections, H1 2015 9
Number of Products under Development for Resistant Pseudomonas Aeruginosa Infections - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Products, H1 2015 14
Assessment by Monotherapy Products, H1 2015 28
Number of Products by Top 10 Targets, H1 2015 30
Number of Products by Stage and Top 10 Targets, H1 2015 31
Number of Products by Top 10 Mechanism of Actions, H1 2015 32
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 33
Number of Products by Top 10 Routes of Administration, H1 2015 34
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 35
Number of Products by Top 10 Molecule Types, H1 2015 36
Number of Products by Stage and Top 10 Molecule Types, H1 2015 37

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing